Dyno Therapeutics Expands Frontiers Network and Unveils Second Annual Genetic Agency Technology Conference
Dyno Therapeutics, a biotechnology company focused on applying artificial intelligence to advance in vivo gene delivery, has announced major updates to two of its strategic initiatives aimed at accelerating innovation in genetic medicine: the Dyno Frontiers Network and the company’s annual Genetic Agency Technology Conference (GATC). The announcements were made during the company’s Scientific Symposium held in conjunction with the American Society of Gene & Cell Therapy Annual Meeting.
The initiatives are designed to help address one of the most significant challenges in modern biotechnology — improving the safe, efficient, and scalable delivery of genetic therapies to patients. Through expanded partnerships, infrastructure support, and collaborative development models, Dyno Therapeutics aims to help therapeutic developers navigate the complex path from early-stage research to clinical development.
The company’s efforts are centered on the concept of “genetic agency,” a term used by Dyno to describe an individual’s ability to take action at the genetic level to improve health outcomes and potentially prevent or treat disease through advanced genetic medicine technologies.
Eric Kelsic, Chief Executive Officer and cofounder of Dyno Therapeutics, said the company launched both the Frontiers initiative and GATC in response to the growing complexity of developing transformative therapies. According to Kelsic, many therapeutic developers face significant scientific, manufacturing, financial, and operational barriers that can slow progress toward bringing new genetic medicines into clinical testing and ultimately to patients.
He explained that Dyno initially established itself through the development of AI-powered gene delivery technologies, particularly in the design of adeno-associated virus (AAV) capsids used to transport genetic material into cells. However, the company now intends to expand beyond technology development alone by helping create a broader ecosystem that connects innovators with the expertise and resources necessary to advance their programs more efficiently.
Kelsic noted that through the Frontiers Network, Dyno aims to simplify access to manufacturing capabilities, development services, regulatory expertise, and investment support for entrepreneurs, researchers, patients, and advocacy groups working on genetic medicine programs. He also emphasized that the Genetic Agency Technology Conference is intended to foster collaboration across the broader gene therapy community and promote collective progress toward expanding patient access to advanced therapeutic options.
A central focus of the announcement was the evolution of the original Dyno Frontiers Program into the newly expanded Dyno Frontiers Network. The initiative has grown from a technology access program into a curated ecosystem connecting therapeutic developers with a broad network of specialized industry partners.
The Frontiers Network is specifically designed to support developers working on a variety of next-generation genetic medicine platforms, including base editing technologies, prime editing systems, epigenetic editors, trans-splicing constructs, vectorized antibodies, and tissue-specific synthetic promoters. These advanced therapeutic approaches represent some of the most rapidly evolving areas within the biotechnology industry and often require highly specialized delivery systems, manufacturing expertise, and development support.
The original Dyno Frontiers Program was first introduced in May 2025 with the goal of providing developers access to Dyno’s AI-designed AAV capsid technologies. These engineered capsids are intended to improve the efficiency and specificity of gene delivery, helping therapeutic payloads reach targeted tissues and cells more effectively.
In November 2025, the initiative expanded significantly with the addition of its first manufacturing partner, Trisk Bio. The inclusion of manufacturing support marked an important step toward transforming the program into a broader collaborative network capable of supporting multiple stages of therapeutic development.
Since then, the Frontiers Network has continued to grow through the addition of manufacturers, contract research organizations (CROs), regulatory consultants, service providers, and investment firms specializing in AAV gene therapy and advanced biologics development.
According to Dyno Therapeutics, the network currently includes 15 therapeutic developers, seven manufacturing organizations, six service providers, and 15 investment partners. The structure of the network is designed to encourage both collaboration and competition among participants while allowing developers to directly engage with partners without requiring Dyno to serve as an intermediary.
This decentralized model creates what the company describes as both a marketplace and a collaborative community. Developers are able to select partners that best meet their scientific, operational, and financial needs, while participating organizations can compete for projects and simultaneously collaborate to support the broader advancement of genetic medicine.
The manufacturing partners currently participating in the Frontiers Network include 3PBiovian, Andelyn Biosciences, Cirsium Biosciences, Franklin Biolabs, PackGene, Revvity, and Trisk Bio.
The service provider segment of the network includes organizations such as Aldevron, BioAnalysis LLC, Charles River Laboratories, Curi Bio, Dark Horse Consulting Group, and Eliquent Life Sciences.
The network also includes a substantial group of venture capital and investment organizations focused on biotechnology and life sciences innovation. These include Andreessen Horowitz, commonly known as a16z, CRV, GV, Insight Partners, Lux Capital, Polaris Partners, and several other investment groups supporting biotechnology startups and early-stage therapeutic development.
Dyno believes the combination of scientific, operational, manufacturing, and financial resources available through the network can help reduce many of the traditional barriers associated with gene therapy development. The company stated that providing access to multiple qualified partners under a unified ecosystem may help accelerate development timelines while reducing operational complexity and development risk.
Tyson Bertmaring, Head of Partnership Success at Dyno Therapeutics, said the company’s long-term approach has focused on helping therapeutic developers overcome critical obstacles that often slow the advancement of innovative therapies.
According to Bertmaring, the Frontiers Network is built on the belief that innovation accelerates when competition and collaboration exist together within the same ecosystem. He explained that aligning incentives across developers, manufacturers, service providers, and investors can create an environment where shared progress benefits all participants while advancing the broader field of genetic medicine.
Bertmaring added that the network’s structure is intended to move the industry closer to a future where genetic therapies become more accessible and scalable for patients around the world.
The announcement also highlights the increasing role of artificial intelligence within the biotechnology and gene therapy industries. AI-driven approaches are becoming increasingly important for designing more effective delivery systems, predicting biological interactions, optimizing manufacturing processes, and accelerating therapeutic discovery.
Dyno Therapeutics has focused heavily on using machine learning and computational biology to improve AAV capsid engineering, an area considered critical for expanding the reach and effectiveness of in vivo gene therapies. Efficient gene delivery remains one of the largest technical hurdles in the field, particularly for therapies targeting specific tissues or requiring high levels of precision and safety.
As the gene therapy market continues expanding, demand for integrated development ecosystems capable of supporting complex programs is expected to increase significantly. Developers often require expertise spanning vector engineering, manufacturing, regulatory strategy, analytical testing, and clinical development — capabilities that are difficult for many early-stage companies to build independently.
By expanding the Frontiers Network and strengthening the collaborative infrastructure surrounding genetic medicine development, Dyno Therapeutics is positioning itself as not only a technology provider but also a strategic ecosystem builder within the rapidly evolving advanced therapies sector.
The company believes that fostering stronger connections between innovators, manufacturers, investors, and service providers can ultimately help accelerate the delivery of next-generation therapies to patients while advancing the broader goal of expanding genetic agency across healthcare.
About Dyno Therapeutics
Dyno Therapeutics is on a mission to build high-performance genetic technologies that transform patients’ lives. Dyno applies AI to build technologies for gene delivery and sequence design that advance “Genetic Agency” – an individual’s ability to take action at the genetic level to live a healthier life – through safe, effective and widely accessible genetic treatments. With frontier AI models and high-throughput in vivo experimentation.
Dyno designs optimized AAV delivery vectors that solve gene delivery challenges across a wide range of therapeutic applications including eye, muscle and CNS. Dyno partners across industries to ensure these life-transforming technologies can help as many patients as possible, including through strategic collaborations with leading gene therapy developers Astellas and Roche and with technology companies including NVIDIA. Dyno’s AI-designed capsids are available for direct licensing and through the Dyno Frontiers Network. Visit www.dynotx.com for more information.
